Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone

Laboratoire de Virologie et Pathogenèse Humaine, Université Lyon 1, CNRS FRE 3011, Lyon, France.
Antiviral therapy (Impact Factor: 3.02). 02/2009; 14(1):55-61.
Source: PubMed


We have previously reported that human adenovirus (HAdV) reference strains clearly show species-dependent resistance to ribavirin, whereas different species of HAdV are equally sensitive to cidofovir. All the serotypes tested were susceptible to cidofovir, whereas only serotypes from species C were sensitive to ribavirin. Here, we aimed to extend these investigations to clinical isolates.
In vitro, we tested 126 isolates obtained from 65 patients included in a European survey of HAdV infection.
Among the 126 isolates tested, all presented cidofovir 50% inhibitory concentration (IC50) in the same range as the HAdV 5 reference strain. Regarding ribavirin, all isolates from species C (79 tested) showed an IC50 comparable with previously reported results for reference strains; however, 24/32, 2/6 and 3/3 tested isolates from species A, B and D, respectively, were shown to have a ribavirin IC50 comparable with the HAdV 5 reference strain (species C), contrary to previous observations for reference strains of the same species. Among patients who were treated with cidofovir for disseminated HAdV infection, > or = 4 sequential isolates could be obtained from 9 patients; no variation in cidofovir susceptibility could be detected.
Cidofovir is active in vitro in all HAdV clinical isolates. Ribavirin was revealed to be active on most HAdV isolates from species A, B and D, and in all isolates from species C. Finally, no resistance to cidofovir became apparent in sequential isolates obtained from treated patients.

Download full-text


Available from: David Carrington, Oct 07, 2014
  • Source
    • "Ribavirin is a nucleoside analogue for which in vitro anti-ADV activity has been reported but it differs against different subtypes. It is active on most ADV isolates from species A, B, and D and in all isolates from species C [49]. There is anecdotal evidence of successful treatment of ADV in immunocompromised patients but larger studies have not been as supportive [43, 50] (reviewed in [15]). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adenovirus (ADV) can cause significant morbidity and mortality in children following haematopoietic stem cell transplantation (HSCT), with an incidence of up to 27% and notable associated morbidity and mortality. T-cell depleted grafts and severe lymphopenia are major risk factors for the development of adenovirus disease after HSCT. Current antiviral treatments are at best virostatic and may have significant side effects. Adoptive transfer of donor-derived virus-specific T cells has been shown to be an effective strategy for the prevention and treatment of ADV infection after HSCT. Here we review progress in the field and present a pathway for the management of adenovirus in the posttransplant setting.
    Advances in Hematology 10/2013; 2013(3):176418. DOI:10.1155/2013/176418
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adenoviruses are emerging as important viral pathogens in solid organ transplant recipients, impacting morbidity, graft survival and even mortality. This review will discuss the current understanding of the epidemiology, diagnosis and therapy of adenovirus infection in transplant recipients. Advances in the field include the use of polymerase chain reaction in the diagnosis of adenoviral infection, a better understanding of the epidemiology, immune response and potential new therapies, including preemptive and adoptive immunotherapy strategies. Adenoviral infections appear to be common, especially in pediatric solid organ transplant. Generally well tolerated, some high-risk patients may develop disseminated disease causing graft failure, which may lead to retransplant and/or death. Antiviral therapy and immunotherapy may play a role in these patients, although prospective controlled data are not available at this time. Although new tools and a better understanding of the epidemiology, risk factors and therapies for adenovirus are beginning to materialize, prospective, controlled trials, using careful definitions, and standardized methodologies need to be performed to more fully clarify these issues in solid organ transplant recipients.
    Current opinion in organ transplantation 10/2009; 14(6):625-33. DOI:10.1097/MOT.0b013e3283324e1b · 2.88 Impact Factor

  • Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 10/2009; 47(1):1-3. DOI:10.1016/j.jcv.2009.09.022 · 3.02 Impact Factor
Show more